Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Phase 3 Active not recruiting 260 enrolled Alexion Pharmaceuticals, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Timeline

Start: 2022-11-21
Primary completion: 2025-05-27
Completion: 2027-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefurulimab	Monoclonal antibody	—	—

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications